Blood Products Market Size, Share, Growth, and Industry Analysis, By Type (Red Blood Cells (RBCs), Fresh Frozen Plasma (FFP), Cryoprecipitate, Platelets, WBCs, Immune Globulins, Whole Blood, Autologous Red Blood Cells, Albumin and Plasma Protein Fraction, Clotting Factors and Cryoprecipitate), By Application (Hospital, Blood Station, Other), Regional Insights and Forecast to 2035

Blood Products Market Overview

Global Blood Products Market size is projected to reach USD 77578.51 Million by 2035, rising from USD 52866.95 Million in 2026 at a CAGR of 4.35%.

The Blood Products Market is a critical component of global healthcare, supporting transfusion medicine, trauma care, surgery, oncology, immunology, and rare disease management. More than 120 million blood donations are collected worldwide annually, while over 85% of donations originate from voluntary unpaid donors. Approximately 40% of global blood collections are generated in high-income countries despite representing only 16% of the global population. Plasma-derived medicinal products remain essential for treating hemophilia, primary immunodeficiency disorders, and coagulation deficiencies. Around 19 million liters of plasma are processed annually for fractionation, supporting the production of albumin, immune globulins, and clotting factors.

The United States remains the largest contributor to global plasma collection and blood product utilization. More than 13 million units of whole blood and red blood cells are collected annually across the country. Over 2,500 hospitals perform blood transfusions, while plasma collection centers continue to expand capacity to meet growing demand for immune globulins and clotting factors. Trauma cases exceeding 20 million emergency department visits annually require substantial blood component availability. Advanced healthcare infrastructure, high donor participation, and strong regulatory oversight support continuous supply. The country also accounts for a substantial share of global plasma fractionation activities and plasma-derived medicinal product manufacturing.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: More than 68% of demand growth is associated with rising chronic disease treatment requirements, while approximately 54% of transfusion utilization is linked to surgical and emergency procedures globally.
• Major Market Restraint: Around 36% of healthcare facilities report blood supply shortages, while nearly 33% of countries continue to experience regulatory and collection inefficiencies affecting availability.
• Emerging Trends: Approximately 47% of healthcare providers are adopting advanced blood management technologies, while AI-supported screening programs have improved operational efficiency by 29%.
• Regional Leadership: North America accounts for approximately 41% of global market activity, supported by strong donor participation rates exceeding 85% voluntary collection levels.
• Competitive Landscape: The top five manufacturers collectively control nearly 63% of plasma-derived product production capacity, reflecting significant industry concentration and technological specialization.
• Market Segmentation: Plasma-derived products contribute approximately 52% of market utilization, while red blood cell products account for nearly 28% of therapeutic demand worldwide.
• Recent Development: More than 34% of manufacturers increased plasma collection investments between 2023 and 2025, while automation adoption expanded by approximately 26%.

Latest Trends

The Blood Products Market is experiencing substantial transformation through plasma collection expansion, digital donor management systems, and advanced fractionation technologies. More than 120 million blood donations are collected globally each year, creating a strong foundation for blood component manufacturing. Voluntary donations exceed 85% of global collections, reflecting increasing awareness regarding blood safety. Plasma-derived medicinal products continue gaining importance due to rising diagnosis rates of immune deficiencies, hemophilia, and neurological disorders. Approximately 19 million liters of plasma are processed annually for fractionation activities. Automation is becoming increasingly important across blood centers. Digital inventory systems have reduced wastage rates by nearly 18%, while automated screening technologies have improved processing speed by approximately 25%. Hospitals are implementing patient blood management programs, with adoption rates exceeding 40% in developed healthcare systems. Demand for immune globulins remains particularly strong because of increased recognition of autoimmune and immunodeficiency conditions.

Market Dynamics

DRIVER

Rising demand for plasma-derived therapies and transfusion medicine

The Blood Products Market is experiencing strong growth due to increasing demand for plasma-derived medicinal products, including immune globulins, albumin, and clotting factors. More than 118 million blood donations are collected globally each year, supporting the production of essential blood components and therapeutic proteins. The prevalence of primary immunodeficiency disorders affects approximately 6 million people worldwide, while hemophilia impacts more than 400,000 individuals globally. Additionally, over 310 million major surgical procedures are performed annually, creating substantial demand for red blood cells, plasma, and platelet transfusions. Growing cancer incidence exceeding 20 million new cases annually and increasing organ transplantation procedures continue to strengthen blood product utilization across healthcare systems. Plasma fractionation capacity expansion and improvements in donor recruitment programs further contribute to market growth.

RESTRAINT

Limited plasma availability and blood donation shortages

Despite increasing demand, blood and plasma shortages remain a significant restraint for the Blood Products Market. Nearly 40% of global blood donations are collected in high-income countries that account for only a small share of the global population. More than 70 countries continue to report periodic shortages of blood components, particularly platelets and plasma-derived therapies. Plasma collection is concentrated in a limited number of countries, creating supply vulnerabilities and dependence on imports. Strict donor eligibility criteria result in rejection rates exceeding 10% in several regions. Additionally, blood products require specialized storage conditions, including temperatures of 2°C to 6°C for red blood cells and below −18°C for frozen plasma, increasing operational complexity and logistics costs. These factors can restrict product availability and market expansion.

OPPORTUNITY

Expansion of plasma fractionation and advanced therapeutic applications

Significant opportunities exist in expanding plasma fractionation capacity and developing next-generation plasma-derived therapies. Global demand for immunoglobulins has increased substantially, with some healthcare markets reporting utilization growth exceeding 8% annually in patient volumes. More than 90 countries remain dependent on imported plasma-derived medicinal products, creating opportunities for domestic manufacturing investments. Advances in purification technologies have improved plasma protein recovery rates by approximately 20%, enhancing production efficiency. Emerging therapeutic applications for immunoglobulins in neurology, immunology, and autoimmune disease management continue expanding the patient pool. Rapid healthcare infrastructure development across Asia-Pacific, Latin America, and the Middle East is creating additional demand for blood products.

CHALLENGE

Regulatory compliance and maintaining blood safety standards

Ensuring blood safety remains one of the most significant challenges facing the Blood Products Market. Every donated unit must undergo multiple screening procedures for infectious diseases, including HIV, hepatitis B, hepatitis C, and syphilis. More than 13 separate quality-control processes may be required before a blood product reaches patients. Regulatory requirements differ across countries, increasing compliance complexity for manufacturers operating internationally. Platelets have a shelf life of approximately 5 days, creating inventory management challenges and contributing to product wastage. Maintaining cold-chain integrity throughout transportation and storage requires continuous monitoring and investment. Furthermore, emerging infectious diseases and evolving pathogen risks require ongoing upgrades to screening technologies and safety protocols, increasing operational burdens across the industry.

Segmentation Analysis

Blood products are segmented by type and application. Plasma-derived products and red blood cells represent the largest utilization categories due to widespread use in hospitals and emergency medicine. Hospitals account for the majority of blood component consumption because of surgical procedures, trauma care, cancer treatments, and organ transplantation. Blood stations play a vital role in collection, testing, storage, and distribution networks.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Type

Red Blood Cells (RBCs): Red blood cells constitute the largest product segment, representing approximately 42%–46% of total blood product utilization globally. More than 85 million RBC units are transfused annually across hospitals worldwide. RBCs are primarily used for trauma management, anemia treatment, cardiovascular surgery, organ transplantation, and emergency medicine. Advanced healthcare systems report leukoreduction adoption rates exceeding 70%, improving transfusion safety and patient outcomes.

Fresh Frozen Plasma (FFP): Fresh Frozen Plasma accounts for approximately 10%–12% of global blood product consumption. FFP contains essential coagulation proteins used in trauma treatment, liver disease management, major surgeries, and coagulation disorder therapies. Hospitals frequently utilize FFP during massive transfusion protocols and emergency procedures. Plasma products are increasingly integrated into critical care settings due to rising cases of severe hemorrhage and trauma-related injuries.

Cryoprecipitate: Cryoprecipitate represents approximately 3%–4% of the Blood Products Market. It contains concentrated fibrinogen, factor VIII, factor XIII, and von Willebrand factor, making it critical for managing bleeding disorders and severe hemorrhage. Trauma centers and specialized hematology departments remain the largest consumers of cryoprecipitate. Increasing diagnosis of coagulation deficiencies and greater awareness of rare bleeding disorders continue supporting demand. Utilization is particularly high during emergency surgical interventions where rapid fibrinogen replacement is required.

Platelets: Platelets account for approximately 18% of blood product demand worldwide. Cancer patients contribute more than 50% of platelet transfusion requirements due to chemotherapy-induced thrombocytopenia. Platelet apheresis procedures have increased by approximately 24% in advanced healthcare institutions, reflecting rising demand from oncology and transplant programs. The short storage life of approximately 5 days requires efficient inventory management and continuous donor recruitment.

WBCs: White blood cell products account for nearly 2% of total market utilization. These specialized products are primarily administered to patients with severe infections, immune deficiencies, and bone marrow suppression. Utilization is concentrated within tertiary care hospitals, transplant centers, and advanced oncology institutions. Although representing a relatively small market share, demand continues to grow as transplant procedures and intensive care treatments increase globally.

Immune Globulins: Immune globulins represent approximately 18%–20% of blood product demand and are among the fastest-growing plasma-derived product categories. In plasma fractionation markets, immunoglobulins account for more than 46% of plasma-derived therapeutic utilization. Their applications include treatment of primary immunodeficiency disorders, autoimmune diseases, neurological conditions, and inflammatory syndromes. Rising diagnosis rates and expanding therapeutic indications continue driving adoption.

Whole Blood: Whole blood contributes approximately 8%–12% of blood product utilization globally. It remains essential in emergency trauma care, military medicine, disaster response, and healthcare systems with limited component separation capabilities. More than 118 million blood donations contribute to whole blood inventory management annually. Trauma centers account for approximately 37% of whole blood utilization due to urgent transfusion requirements. Continued adoption in emergency medicine and pre-hospital care supports demand despite growing preference for component therapy in developed healthcare systems.

Autologous Red Blood Cells: Autologous red blood cells account for approximately 3% of the market. These products are collected from patients before planned surgical procedures and transfused back when required. Autologous transfusion significantly reduces risks associated with donor compatibility and transfusion reactions. Utilization remains particularly high in orthopedic surgery, cardiovascular surgery, and elective procedures involving anticipated blood loss. Increasing awareness of patient blood management strategies supports continued adoption across advanced healthcare systems.

Albumin and Plasma Protein Fraction: Albumin and plasma protein fractions account for approximately 9%–10% of blood product utilization. Albumin remains one of the most widely prescribed plasma-derived therapies due to applications in liver disease, shock management, burns, critical care, and hypoalbuminemia treatment. Expanding intensive care unit admissions and increasing prevalence of chronic liver diseases continue supporting demand. Plasma protein fractions are also utilized in fluid replacement therapies and specialized clinical interventions.

Clotting Factors and Cryoprecipitate: Clotting factors and associated coagulation therapies represent approximately 4%–6% of market demand. These products are critical for managing hemophilia A, hemophilia B, von Willebrand disease, and other bleeding disorders. Increasing diagnosis rates and improved access to treatment have expanded utilization across developed and emerging healthcare markets. Hospitals and specialized hematology centers remain primary consumers. Continuous innovation in coagulation therapies and increased patient awareness support long-term growth within this segment.

By Application

Hospital: Hospitals dominate the Blood Products Market with approximately 70%–75% market share. Surgical procedures, trauma care, oncology treatments, organ transplantation, and intensive care admissions generate substantial blood product demand. Large tertiary hospitals can transfuse between 10,000 and 15,000 blood units annually, while major academic medical centers may exceed 20,000 units. RBCs, plasma, platelets, immune globulins, and clotting factors are routinely utilized across multiple clinical departments.

Blood Station: Blood stations account for approximately 22%–25% of market activity. These facilities are responsible for donor recruitment, blood collection, laboratory testing, processing, storage, and distribution. More than 120 million blood donations are collected globally every year, highlighting the critical role of blood stations within healthcare supply chains. Continuous investments in digital donor management systems, automated testing equipment, and inventory monitoring technologies are enhancing operational efficiency.

Other: Other applications account for approximately 5%–8% of total market demand. This category includes research institutes, military healthcare facilities, specialty clinics, academic centers, and disaster response organizations. Increasing investment in cell therapy research, transfusion medicine studies, and advanced hematology programs contributes to growing utilization. Research institutions are expected to record strong demand growth due to ongoing developments in regenerative medicine, cellular therapies, and blood-derived biological products.

Regional Outlook

Regional performance varies according to healthcare infrastructure, plasma collection capacity, donor participation, and regulatory standards. North America leads global plasma collection and fractionation activities. Europe maintains strong transfusion networks and advanced blood safety systems. Asia-Pacific demonstrates expanding demand due to population growth and healthcare investments. Middle East & Africa continue improving blood collection infrastructure and donor recruitment programs.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America holds the dominant position in the Blood Products Market with approximately 41% of global market share. The region benefits from a highly developed healthcare infrastructure, advanced blood screening systems, and a large network of plasma collection facilities. The United States contributes the majority of regional demand and supplies a substantial portion of the world's source plasma. More than 1,000 plasma collection centers operate across North America, supporting the production of immune globulins, albumin, and clotting factors. The region records more than 43 million transfusion units distributed annually. Red blood cells account for approximately 45% of blood product utilization, while plasma and platelet products represent significant therapeutic categories. Growing prevalence of immunodeficiency disorders, neurological diseases, and hemophilia continues to increase demand for plasma-derived medicinal products.

Europe

Europe accounts for approximately 28% of the global Blood Products Market and remains a key region for blood collection, plasma fractionation, and transfusion medicine. Countries including Germany, France, Italy, Spain, and the United Kingdom maintain highly organized blood donation systems and stringent quality standards. More than 300 plasma collection centers operate across Europe, supporting the production and distribution of essential blood products. Voluntary blood donation rates remain among the highest globally, with several countries reporting participation levels exceeding 90% of total collections. Plasma products, albumin, immune globulins, and coagulation factors are widely utilized in hospitals and specialty treatment centers. Europe contributes approximately 25% of global market activity and continues to invest in plasma self-sufficiency initiatives to reduce dependence on imported plasma supplies.

Asia-Pacific

Asia-Pacific represents approximately 23%–30% of the global Blood Products Market and is considered the fastest-expanding regional market. The region contains more than 60% of the world's population, creating substantial demand for blood transfusions and plasma-derived therapies. China, Japan, India, South Korea, and Australia are major contributors to regional market development. China accounts for nearly 50% of regional plasma production, while Japan and India collectively contribute approximately 35% of regional activity. More than 200 new plasma collection facilities have been established across the region during the past decade, strengthening domestic supply capabilities. Rising surgical volumes, increasing cancer incidence, and growing diagnosis rates of immune disorders continue to support blood product utilization. Government initiatives promoting voluntary blood donation have improved collection volumes, while healthcare infrastructure investments continue expanding access to advanced therapies.

Middle East & Africa

The Middle East & Africa account for approximately 5%–8% of the global Blood Products Market. Although the region currently has a smaller market share, ongoing investments in healthcare infrastructure and blood collection systems are improving market performance. Countries such as Saudi Arabia, the United Arab Emirates, South Africa, and Egypt are leading regional development initiatives. More than 70% of plasma-derived products used in several countries are imported due to limited domestic fractionation capacity. However, governments are increasing investment in plasma collection networks, blood banking modernization, and local manufacturing capabilities. Immunoglobulins account for approximately 45% of plasma-derived product consumption in the region, reflecting growing diagnosis rates of immune deficiencies and autoimmune diseases. Healthcare expansion programs, improved diagnostic services, and rising awareness regarding voluntary blood donation are supporting market growth.

List of Top Blood Products Companies

• Baxter
• CSL
• Grifols
• Octapharma
• BPL
• Kedrion
• Mitsubishi Tanabe
• CBOP
• RAAS
• Hualan Bio
• China Biologic Products Inc
• Shanghai Kehua Bio-Engineering (KHB)
• Hualan Biological Engineering Inc
• Shanghai RAAS Blood Products
• Beijing Tiantan Biological Products
• Zhenxing Biopharmaceutical and Chemical
• Jiangxi Boya Bio-Pharmaceutical
• Sichuan Yuanda Shuyang Pharmaceutical
• Shanghai Institute for Biological Products
• Shanxi Kangbao Biological Product

Top 2 Companies Market Share

• CSL – approximately 23% global plasma-derived product market share.
• Grifols – approximately 19% global plasma-derived product market share.

Investment Analysis and Opportunities

Investment activity in the Blood Products Market is increasingly concentrated on plasma collection infrastructure, fractionation facilities, advanced manufacturing technologies, and supply chain modernization. Global plasma fractionation volumes exceed 45 million liters annually, creating substantial opportunities for capacity expansion and technological upgrades. Major manufacturers continue investing in new plasma collection centers to secure long-term raw material supply and support growing demand for immune globulins, albumin, and clotting factors. One of the most attractive investment areas is plasma fractionation infrastructure. Many countries remain dependent on imported plasma-derived therapies, creating opportunities for domestic manufacturing projects. Immunoglobulins account for more than 46% of plasma fractionation demand in several developing markets, highlighting strong long-term growth potential for investors focusing on specialty blood products. Hospitals and clinics represent more than 85% of end-user demand in emerging healthcare systems, supporting continuous expansion opportunities.

New Product Development

Innovation in the Blood Products Market is increasingly focused on high-purity immune globulins, advanced clotting factors, albumin formulations, and next-generation plasma-derived medicinal products. Immunoglobulins remain the leading plasma-derived therapy category, driving substantial research activity aimed at improving efficacy, safety, and treatment convenience. Manufacturers are developing specialized hyperimmune globulins targeting infectious diseases and immune disorders, while novel recombinant and plasma-derived coagulation factors are expanding treatment options for hemophilia and bleeding disorders. Recent advances in plasma fractionation technology have improved protein recovery rates and product purity. New chromatography-based purification methods are enabling more efficient extraction of immunoglobulins, albumin, and coagulation proteins from collected plasma. Some innovative production processes have demonstrated approximately 20% higher output from the same plasma volume, improving manufacturing efficiency and product availability.

Five Recent Developments (2023-2025)

• CSL expanded plasma collection capacity through additional collection centers, increasing donor processing capability by more than 12%.
• Grifols implemented advanced digital plasma management systems across multiple facilities, improving operational efficiency by approximately 20%.
• Octapharma expanded immune globulin production capacity to address increasing global demand for immunodeficiency treatments.
• Kedrion strengthened plasma fractionation infrastructure with new manufacturing investments supporting higher processing volumes.
• Shanghai RAAS increased plasma collection network coverage, improving domestic supply availability and supporting clotting factor production.

Report Coverage

The Blood Products Market report provides a comprehensive assessment of the global industry across blood collection, plasma procurement, component separation, fractionation, manufacturing, distribution, and end-use applications. The study covers more than 120 million annual blood donations worldwide and evaluates the utilization of major blood products including red blood cells, fresh frozen plasma, platelets, cryoprecipitate, immune globulins, albumin, clotting factors, whole blood, and plasma protein fractions. The report examines supply chain performance, donor participation trends, and blood safety practices across developed and emerging healthcare systems. The analysis includes detailed segmentation by product type and application, highlighting utilization patterns across hospitals, blood stations, specialty clinics, trauma centers, and research institutions. More than 85% of global blood donations originate from voluntary donors, making donor recruitment and retention a key area of evaluation. The report further assesses plasma fractionation activities exceeding 19 million liters annually, with emphasis on the production of immunoglobulins, albumin, and coagulation therapies.

Blood Products Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 52866.95 Million in 2026
Market Size Value By	USD 77578.51 Million by 2035
Growth Rate	CAGR of 4.35% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Red Blood Cells (RBCs) Fresh Frozen Plasma (FFP) Cryoprecipitate Platelets WBCs Immune Globulins Whole Blood Autologous Red Blood Cells Albumin and Plasma Protein Fraction Clotting Factors and Cryoprecipitate By Application : Hospital Blood Station Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample